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1. Introduction with a rate of 304 per 100,000 compared with only 4.6The Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) framework can facilitate
guideline panels’ consideration of health equity issues. More
than 90 organizations worldwide use the GRADE frame-
work to explicitly, systematically, and transparently summa-
rize the effect estimates and rate the certainty (confidence
and quality) of the supporting evidence as well as grade
the strength of recommendations. The recent 15-part
GRADE series in the Journal of Clinical Epidemiology
(JCE ) acknowledged the importance of health equity but
did not provide detailed guidance on how panels should go
about incorporating health equity considerations. This
article is a preamble and rationale for three subsequent arti-
cles in this series in JCE on considering health equity explic-
itly in GRADE guidelines throughout the process (Akl
et al.), rating certainty of evidence (Welch et al.), and in
the evidence to decision framework (Pottie et al.) (Table 1).
Health inequity has been defined as differences in health
that are avoidable and also considered unfair or unjust [1].
Health inequities persist both between and within countries
for many health conditions, including noncommunicable
diseases, communicable diseases, and injuries. Between
countries, life expectancy differentials of up to 30 years still
exist between the highest and lowest income countries (e.g.,
in Swaziland, life expectancy is 49 years compared with
83 years in Japan) [2]. Within countries, gradients in
morbidity are sometimes enormously unfair (e.g., the inci-
dence of tuberculosis [TB] in northern Canadian indige-
nous peoples is 60 times higher than the rest of Canada,per 100,0000 in the rest of Canada) [3].
Health equity is widely recognized as relevant to clin-
ical/public health practice and health policy. For example,
the inverse care law proposes that the availability of medi-
cal care varies inversely according to need across socioeco-
nomic status [4,5]. Other characteristics of individuals and
populations are sometimes also associated with inadequate
access and poor quality medical care, such as gender,
rurality, and ethnicity, and these may not be independent as-
sociations [6]. According to the World Health Organization
(WHO) Commission on Social Determinants of Health, ad-
dressing health inequities requires policies that will not on-
ly modify their structural causes, which include health
systems, but also extend to income inequalities, social pro-
tection, and education policies [7]. In the United States,
there is recognition of the importance and need to reduce
health disparities in documents such as the 2015 calls to
promote health equity with the Affordable Care Act and
in planning digital strategies, as well as an earlier Institute
of Medicine report’’ [8e10].
Promoting health equity reflects a concern and value for
distributive justice for health and health care [11]. The
WHO states that ‘‘the enjoyment of the highest attainable
standard of health is one of the fundamental rights of every
human being without distinction of race, religion, political
belief, economic or social condition’’ [12]. Guidelines can
contribute to advancing health equity globally by explicit
consideration of the impact of individual patient/clinician/
policy-maker decisions on health equity. Reflecting the po-
tential of guidelines to influence health equity, the WHO
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Key points
 Clinical and public health guidelines have a role to
play in promoting health equity by explicitly
considering health equity in the process of guide-
line development, rating certainty and going from
evidence to decision.
 This series of four papers provides guidance and
examples of how to consider health equity in
guideline development.
V.A. Welch et al. / Journal of Clihas included a chapter on equity, human rights, and gender
in their guideline development handbook [13]. The Na-
tional Institute for Health and Care Excellence (NICE)
guideline development manual has explicitly identified
age, ethnicity, and gender as protected characteristics that
must be considered under UK equalities legislation, and
other equity issues may be considered depending on spe-
cific guidelines. Health equity is assessed throughout each
guideline, and these considerations are publicly available
[14]. The GRADE Working Group has recently included
considerations about health equity as one of the factors
affecting the strength of public health and health systems
recommendations, as well as clinical recommendations
from a population perspective, but not clinical recommen-
dations from an individual perspective [15]. Health equity
considerations are listed in the Guidelines International
Network (GIN)dMcMaster University guideline develop-
ment checklist [16]. These examples indicate the awareness
about the contribution of guidelines to promoting health
equity.
Valuing health equity (distributive justice) is one of the
four core moral values of medical ethics along with individ-
ual autonomy, nonmaleficence, and beneficence [17]. These
values need to be explicitly considered in decision making
and resource allocation [18]. For example, prioritizing
health equity over efficiency (i.e., vertical equity) might
lead to reaching fewer people but with a larger benefit for
those reached [19]. Some health care decision-making
bodies, such as the National Health Service (NHS) in theTable 1. Overview of the GRADE equity series
Authors
Welch et al. GRADE equity guidelines 1: considering health equity
Akl et al. GRADE equity guidelines 2: considering health equity
development checklist
Welch et al. GRADE equity guidelines 3: considering health equity
evidence
Pottie et al. GRADE equity guidelines 4: considering health equity
Abbreviation: GRADE, Grading of Recommendations Assessment, DevelUK, have prioritized greater attention and resources for
seriously ill individuals, reflecting a concern for health eq-
uity. If consequences for health equity are not assessed,
health programs and policies run the risk of fostering and
even increasing inequities [20] (Example 1).
Ideally (although not always practical because of re-
sources available for the guideline development), guideline
panels will explicitly weigh equity considerations using a
fair and deliberative process, with opportunity for revisions
based on feedback and consultation with relevant stake-
holders [22]. By making explicit, the discussion regarding
how different equity factors affect the direction and
strength of recommendations, GRADE helps inform the
desired fair and deliberative process and documents consid-
erations that may impact on individual patient/clinician/
policy-maker decisions.
When considering health inequity, guideline panels need
to decide which populations are disadvantaged in relation to
the topic or problem. A useful acronym that can help guide-
line panels considering health equity issues is PROGRESS-
Plus: Place of residence, Race/ethnicity/culture/language,
Occupation, Gender/sex, Religion, Education, Socioeco-
nomic status, or Social capital [6]. In addition, the plus sug-
gests that other characteristics, such as age, disability, sexual
orientation, time-dependent situations, and relationships,
need to be considered [6]. Barriers to care across these char-
acteristics may relate to access/coverage and systems issues
(e.g., infrastructure), provider and/or patient behavior, atti-
tudes, and conscious or unconscious biases [23,24], which
may have a multiplicative effect [23,25].
Debate exists about whether health equity is relevant for
a clinical practice guideline focused on an individual clin-
icianepatient encounter. In 2003, Aldrich et al. [26] pro-
posed that clinical practice guidelines should explicitly
search for evidence about the effect of socioeconomic posi-
tion on effects (e.g., capacity to improve physical activity
behavior may be limited by time constraints for those with
lower income). Dans et al. [27] support this view and
explicitly address how clinical practice guidelines for dys-
lipidemia should consider ethnicity and socioeconomic fac-
tors. We propose that considering evidence for health
equity can inform individual clinical discussions, and the
current GRADE frameworks for considering values/prefer-
ences, trade-offs of benefits and harms, resource use, and
feasibility can be used to consider possible differencesTitle
in GRADE guideline development: introduction and rationale
in GRADE guideline development: equity extension of the guideline
in GRADE guideline development: rating the certainty of synthesized
in GRADE guideline development: evidence to decision process
opment and Evaluation.
Example 1 Resource-stratified guidelines; do they
worsen inequities?
For example, in cancer control, the Breast Health
Global Initiative proposed a four-step approach to
promote improvements in cancer care to indicate
basic resources (e.g., mastectomy), core resources
(e.g., tamoxifen), and enhanced resources depending
on the country setting. The National Comprehensive
Cancer Network has expanded this framework to all
oncology care [21]. Although it is likely that these
guidelines will improve access to the basic
resources, it is uncertain if they could exacerbate
inequities by putting enhanced resources out of
reach of people who face access challenges (e.g.,
because of low income or remote locations).
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ulations. In this series, we outline how this is possible.
Concern for health equity in guidelines has led to in-
stances in which health equity has been considered in
individual-level recommendations. For example, the Cana-
dian migrant health guidelines [28] assessed evidence on
values/preferences related to contraceptive care, TB
screening, and human immunodeficiency virus testing and
found that values vary between migrant and nonmigrant
populations, and clinicians should bear such associations
in mind in their discussion with patients [28]. As another
example, the National Heart Foundation of Australia guide-
line on cardiovascular risk assessment raised issues of
possible underdiagnosis when the Framingham risk equa-
tion is applied in those older than 74 years, with low socio-
economic status or aboriginal background [29].
As an example of how implementation of guidelines
may need to consider health equity, total joint replacement
surgery is offered to men 22 times more than women with
the same level of need [30,31], suggesting that clinicians
should be alert to their biases in offering such surgery, as
well as other system, patient, and setting factors that affect
these decisions. Implementation research needs to consider
sex and gender as well as other characteristics that may in-
fluence both provision and uptake of proven effective inter-
ventions [32]. Some guideline organizations include
specific sections on age, gender, and ethnicity consider-
ations, such as the Scottish Intercollegiate Guideline
Network recommendations that patients should be advised
of viral responsiveness according to ethnicity and age [33].
In low- or middle-income countries where much of
health care is paid for out-of-pocket, socioeconomic, and
gender differences in ability to pay not just for direct but
also indirect costs of care may influence the seeking and
receipt of health care services. For example, in South Af-
rica, among people with TB symptoms, the poorest sought
treatment 2 months later than the least poor andexperienced the greatest income losses [34]. Similarly, in
some countries, health care expenditure is lower for women
and girls than men and boys, such as India [35]. These fac-
tors need to be considered when assessing the feasibility
and acceptability of recommendations and how they will
be implemented in different settings.
Hence, the purpose of this series is to motivate guideline
developers and users of guidelines (clinicians, patients, pol-
icymakers, and decisionmakers) to consider health equity
explicitly and provide guidance on how to do this in the
GRADE guideline development process for all types of
guidelines, including those intended for individual patients,
clinicians, and policy-maker decisions. The series will sum-
marize existing methods and tools for considering health
equity at each of the steps of the GRADE process and pro-
vide examples of good practice.2. Methods
A core team (E.A.A., J.E.-S., K.P., P.T., and V.A.W.) led
by one of us (V.A.W.) conceptualized, planned, organized,
and coordinated the development of the series. The team
specifically decided on the topics to be covered, the struc-
ture of the articles, and the potential contributors using
informal consensus. The topics to be covered were dis-
cussed and agreed with the GRADE Guidance Group and
presented to the GRADE Working Group at three GRADE
meetings in 2014 and 2015. This core team consisted of
clinical, public health, health economics, and methodolog-
ical expertise. All members of the GRADE Working Group
were invited to contribute at meetings and by e-mail.
We searched for articles addressing health equity in any of
the aforementioned guideline types in PubMed and the Na-
tional Guidelines Clearinghouse (Appendix for search strate-
gies) and reviewed online handbooks of organizations known
to consider health equity (i.e., WHO, NICE, National Health
and Medical Research Council [NHMRC], New Zealand,
Agency for Healthcare Research and Quality, Canadian Task
Force, Community Guide). We considered concept articles
[1,24,36],methodological articles [26,27], and reports of pub-
lished guidelines [37e39]. We also considered articles ad-
dressing guideline development methodology [6,16,40e50].
Information from these articles was summarized in tables
for discussion with the core team.
The core team held regular phone and in-person meet-
ings to discuss these summary tables, using informal
consensus approaches, about how to incorporate prior liter-
ature into the series articles, without duplicating coverage
of the literature. One member of the core team drafted each
article, which was then reviewed by the rest of the mem-
bers. The GRADE Working Group lead (V.A.W.) reviewed
all articles for consistent use of terminology and redun-
dancy. Each article was revised on this basis. The articles
were discussed at a GRADE Working Group meeting in
March 2015. They were then circulated via the GRADE
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The articles were then reviewed by the GRADE Guidance
Group to assess consistency with other GRADE articles
and revised based on this feedback.3. Framework for identifying equity-sensitive
questions
When should health equity be assessed in guideline
development? Our group selected, based on review of these
frameworks and informal discussions with GRADE Work-
ing Group members, the prompts described in Box 1 as be-
ing the most consistent with the GRADE Evidence to
Decision process that will also help with identifying
equity-sensitive questions. Consideration of health equity
using this framework may eventually lead to modified rec-
ommendations that apply to everyone or separate recom-
mendations for disadvantaged populations, possibly with
different certainty about effect estimates.
For consistency with the DECIDE project of GRADE, to
describe populations at risk for health inequities, we use the
term disadvantaged throughout this series [15]. We propose
the default template of PROGRESS-Plus [6], but we recog-
nize that many other frameworks are available (e.g.,
SCRAP-Sex, Comorbidities, Race, Age, and Pathophysi-
ology), and the characteristics to consider are needed to
be determined by the guideline panels. Each panel is
encouraged to choose the framework and characteristics
that are most relevant to their setting and topic [6]. We
recognize that there are limitations with the term disadvan-
taged because it may be seen as labeling or stigmatizing
and also depends on the perspective of the person or people
making a normative judgment about disadvantage. Alterna-
tive terms (such as marginalized or underserved) are, how-
ever, no less problematic, and the term disadvantaged isBox 1 Prompts to assess whether a guideline
question is sensitive to health equity
(Oxman et al. [36])
 Are there groups or settings that might be disad-
vantaged in relation to the problem or intervention
of interest?
 Are there plausible reasons for anticipating differ-
ences in the relative effectiveness of the interven-
tion for disadvantaged groups or settings?
 Are there different baseline conditions across
groups or settings that affect the absolute impact
of the intervention or the importance of the prob-
lem for disadvantaged groups or settings?
 Are there important considerations that people im-
plementing the intervention should consider to
ensure that inequities are reduced, if possible,
and that they are not increased?explicit in describing people as experiencing an unfair op-
portunity to attain their health potential [1].4. Overview of the series
This series presents four articles that cover how to
consider health equity at different stages of guideline devel-
opment: (1) This first introduction article describes the ratio-
nale and methods; (2) The second article covers several
stages including, for example, question formulation, scope
definition, panel group composition, and so on (Akl et al.
in this series); (3) the third article covers rating the certainty
of synthesized evidence (Welch et al. in this series); and (4)
the fourth article focuses on the process going from evidence
to recommendation (Pottie et al. in this series) (Table 1). Our
group is committed to disseminating these methods and tools
broadly through open-access Web sites (e.g., Cochrane.
equity.org and the GRADE Working Group online training
modules) and by providing training at relevant conferences
such as the Cochrane Colloquia and the GIN meetings.
Table 2 presents four examples illustrating the consideration
of health equity at different stages of guideline development.5. Conclusion
We anticipate that guideline developers addressing
topics relevant to disadvantaged groups within countries,
and for international organizations that develop guidelines
to be used in low-and middle-income country settings, will
find the series helpful in explicitly considering health eq-
uity issues. Each article in the series presents a research
agenda and set of methodologic challenges, with the aim
of stimulating further research and development of methods
to explicitly consider health equity in future guideline
development processes.Acknowledgments
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Table 2. GRADE guidelines and health equity: four examples
When to think about
health equity in
guideline development
Consideration of health
equity
Community water
fluoridation,
community guide,
2014 [51]
Canadian migrant
health guidelines,
2010 [28]
WHO guidelines on HIV
and STI prevention for
MSM and transgender
people, 2011 [52]
Colombia guidelines on
preventing
complications in
pregnancy and
childbirth, 2013 [53]
Question formulation
and priorities,
scope definition &
group membership
What are the priorities
of disadvantaged
groups or
populations,
and how does this
affect the key
questions?
Logic models were
developed
to include health
disparities as
an outcome of
interest. The panel
included experts
with experience in
socioeconomically
disadvantaged
regions
Priorities were set by
Delphi surveys of
practitioners
working with
migrants. Panel
included primary
care and specialist
practitioners
working with
immigrant and
refugee
populations, and
the methods
included
assessment of
health equity
considerations of
baseline risk;
genetic and cultural
factors; and
adherence variation
[50]
Panel included
content experts
from community-
based
organizations; key
outcomes included
quality of life and
stigma/
discrimination
because of their
perceived relevance
to the population of
interest
Panel included
specialists in health
equity, including
practitioners
working in
disadvantaged low-
income settings
Evidence assessment
(i.e., in systematic
review of the
evidence)
1. Analysis of differ-
ences of effect
(baseline risk and
effectiveness)
2. Targeted
interventions
3. Quality assess-
ment of directness
Assessed evidence
from studies about
effects of
fluoridation in low
socioeconomic
status areas
The panel rated the
directness of
evidence for
immigrant and
refugee populations
explicitly. Evidence
was considered
direct (transferable)
because although
no studies focused
on immigrants or
refugees, the panel
felt that there was
no good reason why
the results would
not apply
Panel searched for
studies targeted
toward or focused
on transgender and
MSM but did not
find any.
Panel decided that
evidence was
direct, although
most studies were
not in MSM or
transgender people
Evidence was
assessed for
specific
disadvantaged
populations in
terms of baseline
risk, e.g., risk of
malnutrition for
low-income
mothers
Evidence to
recommendation
Balance of likely
impact on health
equity with other
factors
Evidence on health
disparities
was considered in
formulating the
recommendation by
including a row in
their summary table
on effect on
disparities
Evidence on
immigrant-specific
baseline risk and
outcomes were
considered in
developing
recommendations
Values of MSM and
transgender people
incorporated by
community
representatives on
the panel and a
survey of MSM and
transgender people.
Resource use in
resource-
constrained setting
was influential in
recommending
against male
circumcision
Equity was considered
in developing
recommendations
by adding a
separate
recommendation for
socioeconomically
disadvantaged
women at high risk
of malnutrition
Abbreviations: GRADE, Grading of Recommendations Assessment, Development and Evaluation; WHO, World Health Organization; HIV, human
immunodeficiency virus; STI, sexually transmitted infection; MSM, men who have sex with men.
Community water fluoridation: (http://www.thecommunityguide.org/oral/supportingmaterials/RRfluoridation.html).
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Search strategies for PubMed and the National Guide-
lines Clearinghouse
Pubmed
(((equity OR inequity OR disparity or ‘‘health inequality’’)))
AND ((‘‘consensus development conference’’[tiab]
OR ‘‘consensus development conference’’[ptyp] OR(‘‘Guidelines as Topic’’[Mesh] OR ‘‘Health Planning
Guidelines’’[Mesh]) OR ‘‘Guideline’’[ptyp] OR ‘‘consensus
statement’’[tiab]))
Filter for Guidelines from Intertasc: http://libguides.sph.
uth.tmc.edu/pubmed_filters.
National Guidelines Clearinghouse
equit* or inequit* or inequalit* or disparit*
